{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:37:10Z","timestamp":1779237430818,"version":"3.51.4"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The exact mechanisms of non-alcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction-associated steatotic liver disease (MASLD), remain unclear. However, oxidative stress is recognized as a factor across all stages of NAFLD. The Pro-oxidant Antioxidant Balance (PAB) method is an important clinical tool that provides an assessment of the balance between oxidants and antioxidant. We aimed to explore oxidative stress in NAFLD using the PAB method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Individuals with NAFLD were recruited in 2021. Eligible participants underwent detailed assessments, including liver elastography for fibrosis evaluation. Blood samples (5 mL) were collected to measure serum PAB levels. The METAVIR score, derived from FibroScan measurements of liver stiffness, categorized fibrosis severity from F0 (no fibrosis) to F4 (advanced fibrosis or cirrhosis).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 102 participants, with a mean age of 50.12 \u00b1 10.03 years. Significant correlations were observed between FibroScan scores and variables such as age, body mass index (BMI), history of chronic diseases, and family history of NAFLD. PAB levels were notably higher in patients with advanced fibrosis (F2 and F3 groups: 86.32 \u00b1 25.53) compared to those in early stages (F0 and F1 groups: 45.36 \u00b1 21.29). Moreover, FibroScan scores showed a significant positive association with PAB values (odds ratio [OR]: 1.07; 95% confidence interval (CI): 1.04, 1.10), even after adjusting for confounding variables (OR: 1.13; 95% CI: 1.07, 1.18).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Elevated PAB levels were strongly associated with advanced stages of liver fibrosis in NAFLD patients, reflecting increased oxidative stress with disease progression. These results highlight the potential of PAB as a marker for monitoring oxidative stress and disease severity in NAFLD. Nevertheless, further large-scale studies are warranted.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1539605","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:52:54Z","timestamp":1741765974000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Association between oxidative stress and liver fibrosis severity in non-alcoholic fatty liver disease: insights from the pro-oxidant antioxidant balance method in a population from Tehran and Mashhad, Iran"],"prefix":"10.3389","volume":"12","author":[{"given":"Hami","family":"Ashraf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Anushiravani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Rayatpisheh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daryoush","family":"Hamidi Alamdari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianaz","family":"Hossieni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behrang","family":"Kazeminezhad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin Mol Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"101209","DOI":"10.1016\/j.jceh.2023.06.009","article-title":"Prevalence of non-alcoholic fatty liver disease in Iran: a systematic review and meta-analysis","volume":"14","author":"Tabaeian","year":"2024","journal-title":"J Clin Exp Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"121185","DOI":"10.1016\/j.lfs.2022.121185","article-title":"Shedding light on non-alcoholic fatty liver disease: pathogenesis, molecular mechanisms, models, and emerging therapeutics","volume":"312","author":"Khairnar","year":"2023","journal-title":"Life Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.gtc.2016.07.003","article-title":"Nonalcoholic fatty liver disease: pathophysiology and management","volume":"45","author":"Carr","year":"2016","journal-title":"Gastroenterol Clin N Am."},{"key":"B6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.livres.2022.05.002","article-title":"Non-alcoholic fatty liver disease development: a multifactorial pathogenic phenomena","volume":"6","author":"Bashir","year":"2022","journal-title":"Liver Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2174\/1566524020666201026162343","article-title":"Critical role of NF\u03baB in the pathogenesis of non-alcoholic fatty liver disease: a widespread key regulator","volume":"21","author":"Franceschetti","year":"2021","journal-title":"Curr Mol Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: from obesity to metabolic syndrome and diabetes","volume":"12","author":"Godoy-Matos","year":"2020","journal-title":"Diabetol Metab Syndr."},{"key":"B9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4103\/2221-1691.338919","article-title":"Non-alcoholic fatty liver disease: epidemiology, pathophysiology and an update on the therapeutic approaches","volume":"12","author":"Abdel-Rahman","year":"2022","journal-title":"Asian Pacific J Trop Biomed."},{"key":"B11","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3390\/antiox10030414","article-title":"Common and novel markers for measuring inflammation and oxidative stress ex vivo in research and clinical practice\u2014which to use regarding disease outcomes?","volume":"10","author":"Menzel","year":"2021","journal-title":"Antioxidants."},{"key":"B12","doi-asserted-by":"publisher","first-page":"100272","DOI":"10.1016\/j.obmed.2020.100272","article-title":"Pro-oxidant\u2013antioxidant balance (PAB) as a prognostic index in assessing the cardiovascular risk factors: a narrative review","volume":"19","author":"Ghazizadeh","year":"2020","journal-title":"Obes Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.clinbiochem.2006.10.017","article-title":"A novel assay for the evaluation of the prooxidant-antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients","volume":"40","author":"Alamdari","year":"2007","journal-title":"Clin Biochem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cgh.2020.04.067","article-title":"Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis","volume":"19","author":"Balakrishnan","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s12325-017-0556-1","article-title":"NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk","volume":"34","author":"Ballestri","year":"2017","journal-title":"Adv Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps","volume":"70","author":"Lonardo","year":"2019","journal-title":"Hepatology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/jgh3.12658","article-title":"Risk factors of nonalcoholic fatty liver disease in lean body mass population: a systematic review and meta-analysis","volume":"5","author":"Alam","year":"2021","journal-title":"JGH Open."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/hep4.1725","article-title":"Impact of aging on liver cells and liver disease: focus on the biliary and vascular compartments","volume":"5","author":"Baiocchi","year":"2021","journal-title":"Hepatol Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12944-023-01905-0","article-title":"Genetic predisposition to nonalcoholic fatty liver disease: insights from ANGPTL8 gene variants in Iranian adults","volume":"22","author":"Saghafi","year":"2023","journal-title":"Lipids Health Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.2174\/1381612825666190119113836","article-title":"Genetics of nonalcoholic fatty liver disease: a 2018 update","volume":"24","author":"Valenti","year":"2018","journal-title":"Curr Pharmaceut Design."},{"key":"B21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41575-019-0169-z","article-title":"NAFLD in children: new genes, new diagnostic modalities and new drugs","volume":"16","author":"Nobili","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.22037\/ghfbb.v12i2.1482","article-title":"Pro-oxidant antioxidant balance in patients with non-alcoholic fatty liver disease","volume":"12","author":"Nobakht Motlagh Ghoochani","year":"2019","journal-title":"Gastroenterol Hepatol Bed Bench."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.clnu.2023.06.015","article-title":"Oxidative balance score is inversely associated with the incidence of non-alcoholic fatty liver disease","volume":"42","author":"Cho","year":"2023","journal-title":"Clin Nutr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrgastro.2016.97","article-title":"Liver regeneration - mechanisms and models to clinical application","volume":"13","author":"Forbes","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1539605\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:52:56Z","timestamp":1741765976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1539605\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":24,"alternative-id":["10.3389\/fmed.2025.1539605"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1539605","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"article-number":"1539605"}}